Canertinib (dihydrochloride)
CAT:
804-HY-10367A-01
Size:
5 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Canertinib (dihydrochloride)
UNSPSC Description:
Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice[1][2][3][4].Target Antigen:
EGFR; OrthopoxvirusType:
Reference compoundRelated Pathways:
Anti-infection;JAK/STAT Signaling;Protein Tyrosine Kinase/RTKApplications:
Cancer-Kinase/proteaseField of Research:
Cancer; InfectionAssay Protocol:
https://www.medchemexpress.com/Canertinib-dihydrochloride.htmlPurity:
99.68Solubility:
DMSO : 62.5 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)Smiles:
C=CC(NC1=CC2=C(N=CN=C2C=C1OCCCN3CCOCC3)NC4=CC=C(C(Cl)=C4)F)=O.[H]Cl.[H]ClMolecular Weight:
558.86References & Citations:
[1]Smaill JB, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97.|[2]Djerf Severinsson EA, et al. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochem Biophys Res Commun. 2011 Oct 28;414(3):563-8.|[3]McAndrews KM, et, al. Mechanisms associated with biogenesis of exosomes in cancer. Mol Cancer. 2019 Mar 30;18(1):52.|[4]Smee DF, et, al. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19(3):115-24.Harvard Medical School LINCS LIBRARY|J Cell Sci. 2015 Sep 1;128(17):3317-29. |Biochemistry. 2017 Jun 13;56(23):2921-2927.|Biochemistry. 2018 Feb 27;57(8):1369-1379.|bioRxiv. 2023 Oct 6.|J Biol Chem. 2012 Mar 23;287(13):9742-52.|J Med Chem. 2019 May 9;62(9):4772-4778.|Oncotarget. 2020 Nov 3;11(44):3921-3932.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C (Powder, sealed storage, away from moisture)Clinical Information:
Phase 2CAS Number:
289499-45-2